Citations

Showing 10 of 108094 citations.

Baseline Characteristics Associated with Good Collateral Status Using Hypoperfusion Index as an Outcome
Hamam, Omar , Garg, Tushar , Elmandouh, Omar, Wang, Richard , Aslan, Alperen , Ahmed, Amara, Moustafa, Abdallah , Yedavalli, Vivek , Yedavalli, Vivek S

Mayo Clinic

Tomography | July 25, 2022 | Volume: 8 | Issue: 4 | Pages: 1885-1894

10.3390/tomography8040159 | PMID 35894024 Get It

Up to 30% of ischemic stroke cases are due to large vessel occlusion (LVO), causing significant morbidity. Studies have shown that the collateral circulation of patients with acute ischemic stroke (AIS) secondary to LVO can predict their clinical and radiological outcomes. The aim of this study is to identify baseline patient characteristics that can help predict the collateral status of these patients for improved triage. In this IRB approved retrospective study, consecutive patients presenting with AIS secondary to anterior circulation LVO were identified between September 2019 and August 2021. The baseline patient characteristics, laboratory values, imaging features and outcomes were collected using a manual chart review. From the 181 consecutive patients initially reviewed, 54 were confirmed with a clinical diagnosis of AIS and anterior circulation LVO. In patients with poor collateral status, the body mass index (BMI) was found to be significantly lower compared to those with good collateral status (26.4 ± 5.6 vs. 31.7 ± 12.3; p = 0.045). BMI of >35 kg/m2 was found to predict the presence of good collateral status. Age was found to be significantly higher (70.5 ± 9.6 vs. 58.9 ± 15.6; p = 0.034) in patients with poor collateral status and M1 strokes associated with older age and BMI.
A Primer Genetic Toolkit for Exploring Mitochondrial Biology and Disease Using Zebrafish
Sabharwal, Ankit , Campbell, Jarryd M. , Schwab, Tanya L., WareJoncas, Zachary , Wishman, Mark , Ata, Hirotaka , Liu, Wiebin, Hunter, Danielle E., Bergren, Jake D., Urban, Mark D. , Urban, Rhianna , Holmberg, Shannon R. , Kar, Bibekananda , Ekker, Stephen C. , Wishman, Mark D, Ichino, Noriko , Urban, Mark D , Kar, Bibekananda , Cook, Alex, Ding, Yonghe , Ekker, Stephen C , Sabharwal, Ankit , Cook, Alex Richard , Xu, Xiaolei , Clark, Karl J.

Mayo Clinic

Genes | July 24, 2022 | Volume: 13 | Issue: 8 | Pages: 1317

10.3390/genes13081317 | PMID 35893052 Get It

Mitochondria are a dynamic eukaryotic innovation that play diverse roles in biology and disease. The mitochondrial genome is remarkably conserved in all vertebrates, encoding the same 37-gene set and overall genomic structure, ranging from 16,596 base pairs (bp) in the teleost zebrafish (Danio rerio) to 16,569 bp in humans. Mitochondrial disorders are amongst the most prevalent inherited diseases, affecting roughly 1 in every 5000 individuals. Currently, few effective treatments exist for those with mitochondrial ailments, representing a major unmet patient need. Mitochondrial dysfunction is also a common component of a wide variety of other human illnesses, ranging from neurodegenerative disorders such as Huntington’s disease and Parkinson’s disease to autoimmune illnesses such as multiple sclerosis and rheumatoid arthritis. The electron transport chain (ETC) component of mitochondria is critical for mitochondrial biology and defects can lead to many mitochondrial disease symptoms. Here, we present a publicly available collection of genetic mutants created in highly conserved, nuclear-encoded mitochondrial genes in Danio rerio. The zebrafish system represents a potentially powerful new opportunity for the study of mitochondrial biology and disease due to the large number of orthologous genes shared with humans and the many advanced features of this model system, from genetics to imaging. This collection includes 15 mutant lines in 13 different genes created through locus-specific gene editing to induce frameshift or splice acceptor mutations, leading to predicted protein truncation during translation. Additionally, included are 11 lines created by the random insertion of the gene-breaking transposon (GBT) protein trap cassette. All these targeted mutant alleles truncate conserved domains of genes critical to the proper function of the ETC or genes that have been implicated in human mitochondrial disease. This collection is designed to accelerate the use of zebrafish to study many different aspects of mitochondrial function to widen our understanding of their role in biology and human disease.
Development and implementation of an electronic Clinical Dementia Rating and Financial Capacity Instrument‐Short Form
Howell, Taylor, Gummadi, Shilpa, Bui, Chau, Santhakumar, Jessica , Knight, Kristen, Roberson, Erik D. , Marson, Daniel , Chambless, Carol, Gersteneker, Adam, Martin, Roy C. , Kennedy, Richard , Morris, John C. , Moulder, Krista L., Mayo, Connie, Carroll, Maria , Li, Yan , Petersen, Ronald C. , Nosheny, Rachel L. , Mackin, Scott, Weiner, Michael W. , Stricker, Nikki H. , Roberson, Erik , Kennedy, Richard E , Morris, John C , Zhang, Yue

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | July 24, 2022 | Volume: 14 | Issue: 1 | Pages: No page available

10.1002/dad2.12331 | PMID 35898521 Get It

AbstractIntroductionTo address the need for remote assessments of cognitive decline and dementia, we developed and administered electronic versions of the Clinical Dementia Rating (CDR®) and the Financial Capacity Instrument‐Short Form (FCI‐SF) (F‐CAP®), called the eCDR and eFCI, respectively.MethodsThe CDR and FCI‐SF were adapted for remote, unsupervised, online use based on item response analysis of the standard instruments. Participants completed the eCDR and eFCI first in clinic, and then at home within 2 weeks.ResultsOf the 243 enrolled participants, 179 (73%) cognitively unimpaired (CU), 50 (21%) with mild cognitive impairment (MCI) or dementia, and 14 (6%) with an unknown diagnosis, 84% and 85% of them successfully completed the eCDR and eFCI, respectively, at home.DiscussionThese results show initial feasibility in developing and administering online instruments to remotely assess and monitor cognitive decline along the CU to MCI/very mild dementia continuum. Validation is an important next step.
Cardiac resynchronization therapy response in cardiac sarcoidosis
Shabtaie, Samuel A. , Sehrawat, Ojasav , Lee, Justin Z. , Cha, Yong‐Mei , Mulpuru, Siva K. , Kowlgi, Gurukripa N. , Siontis, Konstantinos C. , Rosenbaum, Andrew , Bois, John P. , AbouEzzeddine, Omar F. , Asirvatham, Samuel J. , Deshmukh, Abhishek , Kowlgi, Narayan G , Rosenbaum, Andrew N , Noseworthy, Peter A , Asirvatham, Samuel J , DeSimone, Christopher V , Deshmukh, Abhishek J , AbouEzzeddine, Omar F , Noseworthy, Peter A. , DeSimone, Christopher V.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | July 23, 2022 | Volume: 33 | Issue: 9 | Pages: 2072-2080

10.1111/jce.15631 | PMID 35870183 Get It

AbstractIntroductionCardiac sarcoidosis (CS) is a nonischemic cardiomyopathy (NICM) characterized by infiltration of noncaseating granulomas involving the heart with highly variable clinical manifestations that can include conduction abnormalities and systolic heart failure. Cardiac resynchronization therapy (CRT) has shown significant promise in NICM, though little is known about its efficacy in patients with CS.ObjectiveTo determine if CRT improved cardiac remodeling in patients with CS.MethodsWe retrospectively reviewed all patients with a clinical or histological diagnosis of CS who underwent CRT implantation at the Mayo Clinic enterprise from 2000 to 2021. Baseline characteristics, imaging parameters, heart failure hospitalizations and need for advanced therapies, and major adverse cardiac events (MACE) were assessed.ResultsOur cohort was comprised of 55 patients with 61.8% male and a mean age of 58.7 ± 10.9 years. Eighteen (32.7%) patients had definite CS, 21 (38.2%) had probable CS, while 16 (29.1%) had presumed CS, and 26 (47.3%) with extracardiac sarcoidosis. The majority underwent CRT‐D implantation (n = 52, 94.5%) and 3 (5.5%) underwent CRT‐P implantation with 67.3% of implanted devices being upgrades from prior pacemakers or implantable cardioverter defibrillators. At 6 months postimplantation there was no significant improvement in ejection fraction (34.8 ± 10.9% vs. 37.7 ± 14.2%, p = .331) or left ventricular end‐diastolic diameter (58.5 ± 10.2 vs. 57.5 ± 8.1 mm, p = .236), though mild improvement in left ventricular end systolic diameter (49.1 ± 9.9 vs. 45.7± 9.9 mm, p < .0001). Within the first 6 months postimplantation, 5 (9.1%) patients sustained a heart failure hospitalization. At a mean follow‐up of 4.1± 3.7 years, 14 (25.5%) patients experienced a heart failure hospitalization, 11 (20.0%) underwent cardiac transplantation, 1 (1.8%) underwent left ventricular assist device implantation and 7 (12.7%) patients died.ConclusionsOur findings suggest variable response to CRT in patients with CS with no overall improvement in ventricular function within 6 months and a substantial proportion of patients progressing to advanced heart failure therapies.
Insurance-based disparities impact survival outcomes in Waldenström macroglobulinemia within the United States
Chohan, Karan , Abeykoon, Jithma P. , Ansell, Stephen M. , Gertz, Morie A. , Kapoor, Prashant , Paulus, Aneel , Ailawadhi, Sikander , Reeder, Craig B. , Witzig, Thomas E. , Lacy, Martha Q. , Kyle, Robert A. , Chohan, Karan L, Go, Ronald S , Paludo, Jonas , Witzig, T.E. , Gertz, Morie A , Ailawadhi, Sikander , Paulus, Aneel , Chohan, Karan L , Habermann, Thomas M. , Go, Ronald S. , Paludo, Jonas

Mayo Clinic

Leukemia & Lymphoma | July 23, 2022 | Volume: 63 | Issue: 12 | Pages: 2879-2888

10.1080/10428194.2022.2102623 | PMID 35876190 Get It

Presenting Symptomatology for Patients With Nasal Septal Perforation: Application of the NOSE‐Perf Scale
Taylor, Cullen M. , Marino, Michael J. , Bansberg, Stephen F. , Taylor, Cullen

Mayo Clinic

The Laryngoscope | July 23, 2022 | Volume: 133 | Issue: 6 | Pages: 1315-1320

10.1002/lary.30299 | PMID 35869840 Get It

ObjectiveTo objectively identify and quantitate presenting nasal symptoms in patients with a septal perforation using the validated NOSE‐Perf scale.Study DesignCase series retrospective review.MethodsThe medical records from August 2018 through January 2022 of patients at a tertiary care academic center with a septal perforation, and who completed the NOSE‐Perf questionnaire, were reviewed. Perforation symptoms were identified and quantified using the 12‐item NOSE‐Perf scale (score range 0–48). NOSE‐Perf findings were correlated to patient demographics, perforation etiology, and perforation length. NOSE‐Perf scores of patients who pursued treatment were compared with those who did not.ResultsNOSE‐Perf data were collected from 202 patients. Nasal crusting was noted in 94.1% of patients and was the most severe symptom reported (mean 2.9 of 4.0). Nasal congestion, difficulty breathing, and nasal obstruction followed in prevalence and severity. The mean total NOSE‐Perf score was 23.7. Linear regression analysis demonstrated a weakly negative association of NOSE‐Perf score with patient age and weakly positive association with increasing perforation length. NOSE‐Perf scores were significantly higher in women and in patients pursuing treatment.ConclusionThis is the first study to use the validated NOSE‐Perf scale to objectively characterize and establish baseline septal perforation symptomatology. The NOSE‐Perf scale can play a role in the standardization of perforation evaluation and treatment outcomes assessment. Laryngoscope, 133:1315–1320, 2023
COVID‐19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies
Gil‐Vila, Albert , Ravichandran, Naveen , Selva-O’Callaghan, Albert , Sen, Parikshit , Nune, Arvind , Gaur, Prithvi Sanjeevkumar , Joshi, Mrudula , Agarwal, Vishwesh , Kardeş, Sinan , Kim, Minchul , Day, Jessica , Milchert, Marcin , Salim, Babur , Velikova, Tsvetelina , Gracia‐Ramos, Abraham Edgar , Parodis, Ioannis , Nikiphorou, Elena , Tan, Ai Lyn , Chatterjee, Tulika , Ziadé, Nelly , Kuwana, Masataka , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, COVAD Study, Singh, Yogesh Preet , Needham, Merrilee , Loarce‐Martos, Jesus , Ordóñez, Andrea Bran , Gupta, Latika , Lilleker, James B , Joshi, Mrudula , Agarwal, Vishwesh , Kardes, Sinan , Kim, Minchul , Day, Jessica , Makol, Ashima , Milchert, Marcin , Gheita, Tamer , Salim, Babur , Velikova, Tsvetelina , Gracia-Ramos, Abraham Edgar , Parodis, Ioannis , Nikiphorou, Elena , Tan, Ai Lyn , Chatterjee, Tulika , Cavagna, Lorenzo , Saavedra, Miguel A , Shinjo, Samuel Katsuyuki , Ziade, Nelly , Knitza, Johannes , Kuwana, Masataka , Distler, Oliver , Chinoy, Hector , Agarwal, Vikas , Aggarwal, Rohit , Gupta, Latika , Selva O'Callaghan, Albert , Nune, Arvind , Naveen, R , Sen, Parikshit , Singh, Yogesh Preet , Gonzalez, Raquel Arànega, Makol, Ashima , Gheita, Tamer A. , Shinjo, Samuel Katsuyuki , Distler, Oliver , Aggarwal, Rohit , Group, COVAD Study

Mayo Clinic

Muscle & Nerve | July 23, 2022 | Volume: 66 | Issue: 4 | Pages: 426-437

10.1002/mus.27681 | PMID 35869701 Get It

AbstractIntroduction/AimsIn this study we investigated COVID‐19 vaccination–related adverse events (ADEs) 7 days postvaccination in patients with idiopathic inflammatory myopathies (IIMs) and other systemic autoimmune and inflammatory disorders (SAIDs).MethodsSeven‐day vaccine ADEs were collected in an international patient self‐reported e‐survey. Descriptive statistics were obtained and multivariable regression was performed.ResultsTen thousand nine hundred respondents were analyzed (1227 IIM cases, 4640 SAID cases, and 5033 healthy controls [HCs]; median age, 42 [interquartile range, 30‐455] years; 74% female; 45% Caucasian; 69% completely vaccinated). Major ADEs were reported by 76.3% of the IIM patients and 4.6% reported major ADEs. Patients with active IIMs reported more frequent major (odds ratio [OR], 2.7; interquartile range [IQR], 1.04‐7.3) and minor (OR, 1.5; IQR, 1.1‐2.2) ADEs than patients with inactive IIMs. Rashes were more frequent in IIMs (OR, 2.3; IQR, 1.2‐4.2) than HCs. ADEs were not impacted by steroid dose, although hydroxychloroquine and intravenous/subcutaneous immunoglobulins were associated with a higher risk of minor ADEs (OR, 1.9; IQR, 1.1‐3.3; and OR, 2.2; IQR, 1.1‐4.3, respectively). Overall, ADEs were less frequent in inclusion‐body myositis (IBM) and BNT162b2 (Pfizer) vaccine recipients.DiscussionSeven‐day postvaccination ADEs were comparable in patients with IIMs, SAIDs, and HCs, except for a higher risk of rash in IIMs. Patients with dermatomyositis with active disease may be at higher risk, and IBM patients may be at lower risk of specific ADEs. Overall, the benefit of preventing severe COVID‐19 through vaccination likely outweighs the risk of vaccine‐related ADEs. Our results may inform future guidelines regarding COVID‐19 vaccination in patients with SAIDs, specifically in those with IIMs. Studies to evaluate long‐term outcomes and disease flares are needed to shed more light on developing future COVID‐19 vaccination guidelines.
Smoking Cessation Interventions in Indigenous North Americans: A Meta-Narrative Systematic Review
Rusk, Ann M. , Kennedy, Cassie C. , Kanj, Amjad N, Murad, Mohammad H, Hassett, Leslie C. , Kennedy, Cassie C , Rusk, Ann , Kanj, Amjad , Murad, M. Hassan

Mayo Clinic

Nicotine and Tobacco Research | July 23, 2022 | Volume: 25 | Issue: 1 | Pages: 3-11

10.1093/ntr/ntac181 | PMID 35869642 Get It

Abstract Introduction Indigenous North Americans have the highest cigarette smoking prevalence among all racial and ethnic groups in the United States. We seek to identify effective components of smoking cessation interventions in Indigenous people in the United States associated with favorable cessation outcomes. Methods A review of literature studying smoking cessation interventions in Indigenous North Americans (American Indians and Alaska Natives) from January 2010 through August 2021 was completed. The primary objective of this study was to identify components of interventions associated with positive smoking cessation outcomes in Indigenous people. The studies identified were synthesized in a meta-narrative approach. Results Ten studies out of 608 titles were included (6 randomized trials, 2 single-arm studies, 1 cohort study, and 1 prospective observational study). Five categories of smoking cessation interventions were identified; phone or web-based tools, culturally-tailored interventions, the inclusion of Indigenous study personnel, pharmaceutical cessation aids, and behavioral health interventions. Phone and web tools, cultural tailoring, and inclusion of Indigenous personnel conditions inconsistently influenced smoking cessation. Pharmaceutical aids were viewed favorably among participants. Individualized behavioral counseling sessions were effective at promoting smoking cessation, as was input from local communities in the planning and implementation phases of study. Conclusion A successful smoking cessation intervention in Indigenous North Americans includes Tribal or community input in intervention design and implementation; should provide individualized counseling sessions for participants, and offer access to validated smoking cessation tools including pharmacotherapy. Implications This study identifies a paucity of smoking interventions utilizing standard of care interventions in Indigenous North Americans. Standard of care interventions including individualized cessation counseling and pharmacotherapy were effective at promoting cessation. The use of novel culturally tailored cessation interventions was not more effective than existing evidence-based care with the exception of including Tribal and local community input in intervention implementation. Future smoking cessation interventions in Indigenous North Americans should prioritize the use of standard of care cessation interventions.
E-218 Risk factors of unexplained early neurological deterioration following endovascular treatment in patient with large vessel occlusion: systematic review and meta-analysis
Abbasi, Mehdi , Larco, J Arturo, Vega, C Perez-, Huynh, T, Larco, Jorge Arturo , Perez‐Vega, Carlos , Huynh, Thien

Mayo Clinic

SNIS 19th annual meeting electronic poster abstracts | July 23, 2022 | Volume: No volume available | Issue: No issue available | Pages: A198.2-A199

10.1136/neurintsurg-2022-snis.329 Get It

E-013 Dual microcatheter pressure cooker embolization technique for treatment of thoracolumbar cerebrospinal fluid venous fistulas
Miller, D, Huynh, T, Parizadeh, D

Mayo Clinic

SNIS 19th annual meeting electronic poster abstracts | July 23, 2022 | Volume: No volume available | Issue: No issue available | Pages: A81.1-A81

10.1136/neurintsurg-2022-snis.124 Get It